o NoneEntity Type
0001321834
None
Akers Biosciences Inc
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
 Akers Biosciences, Inc.
Jurisdiction of Incorporation/OrganizationNEW JERSEY 
Year of Incorporation/Organization
  x Over Five Years Ago
  o Within Last Five Years (Specify Year)  
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 Akers Biosciences, Inc. 
Street Address 1Street Address 2
 201 GROVE ROAD 
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 THOROFARE NEW JERSEY 08086 (856) 848-8698 



3. Related Persons
Last NameFirst NameMiddle Name
BensonStuart
Street Address 1Street Address 2
201 Grove Road
CityState/Province/CountryZIP/Postal Code
ThorofareNEW JERSEY08086
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 Chief Financial Officer

Last NameFirst NameMiddle Name
SchreiberChristopherC.
Street Address 1Street Address 2
201 Grove Road
CityState/Province/CountryZIP/Postal Code
ThorofareNEW JERSEY08086
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 President and Chief Executive Officer

Last NameFirst NameMiddle Name
SilvermanJoshua
Street Address 1Street Address 2
201 Grove Road
CityState/Province/CountryZIP/Postal Code
ThorofareNEW JERSEY08086
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 Chairman of the Board of Directors

Last NameFirst NameMiddle Name
WhiteBillJ.
Street Address 1Street Address 2
201 Grove Road
CityState/Province/CountryZIP/Postal Code
ThorofareNEW JERSEY08086
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

 
Last NameFirst NameMiddle Name
SchroederRobertC.
Street Address 1Street Address 2
201 Grove Road
CityState/Province/CountryZIP/Postal Code
ThorofareNEW JERSEY08086
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   o Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  o Pharmaceuticals  o Telecommunications
  o Investment Banking  x Other Health Care  o Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance o Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
x Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale 2020-11-11 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests x Equity
o Tenant-in-Common Securities o Debt
o Mineral Property Securities o Option, Warrant or Other Right to Acquire Another Security
x Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security o Other (describe)
  


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 0 USD

12. Sales Compensation
RecipientRecipient CRD Number o None
 Katalyst Securities LLC 112494
(Associated) Broker or Dealer x None(Associated) Broker or Dealer CRD Number x None
    
Street Address 1Street Address 2
 630 THIRD AVENUE 5TH FLOOR
City State/Province/CountryZIP/Postal Code
 NEW YORK NEW YORK 10017
State(s) of Solicitation o All States o Foreign/Non-US
 CALIFORNIA
 CONNECTICUT
 FLORIDA
 GEORGIA
 ILLINOIS
 INDIANA
 IOWA
 MARYLAND
 MASSACHUSETTS
 MICHIGAN
 NEW JERSEY
 NEW YORK
 OHIO
 PENNSYLVANIA
 SOUTH DAKOTA
 

 



13. Offering and Sales Amounts
Total Offering Amount $ 18067000 USD o Indefinite
Total Amount Sold $ 18067000 USD 
Total Remaining to be Sold $ 0 USD o Indefinite
 
Clarification of Response (if Necessary)
 Represents 9,765,933 shares of common stock or pre-funded warrants and warrants to purchase 9,765,933 shares of common stock at $2.06 per share.


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 56


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 1174355 USD o Estimate
Finders' Fees$ 0 USD o Estimate
 
Clarification of Response (if Necessary)
 In addition to the sales commission noted above, the placement agent also received a warrant to purchase 390,368 shares of Issuer's common stock at $1.85 per share.


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o
Akers Biosciences (NASDAQ:AKER)
過去 株価チャート
から 6 2024 まで 7 2024 Akers Biosciencesのチャートをもっと見るにはこちらをクリック
Akers Biosciences (NASDAQ:AKER)
過去 株価チャート
から 7 2023 まで 7 2024 Akers Biosciencesのチャートをもっと見るにはこちらをクリック

ニュース - Akers Biosciences, Inc.

Real-Time news about Akers Biosciences Inc (ナスダック市場): 0 recent articles

その他のAkers Biosciences, Inc.ニュース記事

最近閲覧した銘柄